Entecavir (ETV) monohydrate

DRUG3 trials

Sponsors

Janssen Sciences Ireland UC, Janssen Research & Development, LLC

Conditions

Hepatitis B, ChronicHepatitis D, Chronic

Phase 2

A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

CompletedNCT04129554

Janssen Sciences Ireland UCHepatitis B, Chronic

Start: 2019-11-06End: 2022-06-09Updated: 2025-02-04

A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus

CompletedNCT04535544

Janssen Research & Development, LLCHepatitis D, Chronic

Start: 2020-09-17End: 2025-03-05Updated: 2025-04-25

A Study of JNJ-73763989, JNJ-56136379, Nucleos(t)Ide Analogs, and Pegylated Interferon Alpha-2a in Virologically Suppressed Participants With Chronic Hepatitis B Virus Infection

CompletedNCT04667104

Janssen Research & Development, LLCHepatitis B, Chronic

Start: 2021-02-01End: 2023-04-17Updated: 2024-07-03

Related Papers

Peginterferon-alpha-2a add-on to treatment with siRNA JNJ-73763989 in virologically suppressed chronic hepatitis B: The phase II PENGUIN study.

2025-07-09

Serum levels of hepatitis B core antibodies and hepatitis B core-related antigen at the time of nucleos(t)ide analog cessation and risk of severe flares in patients with chronic hepatitis B.

2025-02-261 citations

JNJ-73763989 and bersacapavir treatment in nucleos(t)ide analogue-suppressed patients with chronic hepatitis B: REEF-2

Journal of Hepatology2024-04-0534 citations